{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-26-000048","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2026-08-03T20:02:02+00:00","discovered_at":"2026-08-03T20:03:00.699605+00:00","generated_at":"2026-08-03T20:03:09.052710+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Keros Therapeutics Q2 2026 net loss $28.7M; initiates Phase 2 DMD trial for rinvatercept","bullets":["Net loss of $28.7M in Q2 2026 vs $30.7M in Q2 2025; R&D expenses down to $22.3M from $43.5M.","Cash and cash equivalents $257.6M as of June 30, 2026; expected to fund operations into first half 2028.","Initiated Phase 2 clinical trial of rinvatercept in Duchenne muscular dystrophy; initial data expected first half 2027.","General and administrative expenses decreased to $8.6M from $14.5M due to restructuring and lower professional fees."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-26-000048","json":"https://secwatch.observer/filing/0001664710-26-000048.json","markdown":"https://secwatch.observer/filing/0001664710-26-000048.md","text":"https://secwatch.observer/filing/0001664710-26-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000048/0001664710-26-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000048/kros-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T20:03:09.052710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}